Drug intelligence / Profile preview

ACT-777991

Development stage: Phase 2
Lead developer: Idorsia
Modality: Small Molecules
Administration: Oral

Overview

ACT-777991 is a highly potent, orally available small molecule antagonist of the C-X-C chemokine receptor 3 (CXCR3), developed by Idorsia Pharmaceuticals. It acts as an insurmountable and selective CXCR3 antagonist, blocking the migration of activated T cells to sites of inflammation by inhibiting the binding of its ligands (CXCL9, CXCL10, and CXCL11) to the receptor. This mechanism is relevant in autoimmune diseases where CXCR3-expressing T cells contribute to tissue damage. Preclinical studies have shown that ACT-777991 inhibits chemotaxis of CXCR3+ T cells and demonstrates efficacy in models of type 1 diabetes. The drug has advanced into Phase I clinical trials for type 1 diabetes mellitus and vitiligo.

Other names: compound 8acompound8acompound-8a

Targets

CCR3 (C-C chemokine receptor type 3)

Beyond the preview

Go deeper on ACT-777991.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACT-777991.

Explore the full profile